NBIX CRO exercises options, sells 2,261 shares

NEUROCRINE BIOSCIENCES INC Chief Regulatory Officer Ingrid Delaet reported an option exercise combined with a routine share sale.

Rhea-AI Filing Summary

NEUROCRINE BIOSCIENCES INC Chief Regulatory Officer Ingrid Delaet reported an option exercise combined with a routine share sale. On May 29, 2026, she exercised non-qualified stock options for 2,261 shares of common stock at an exercise price of $79.02 per share and sold 2,261 shares in an open-market transaction at $156.71 per share. After these transactions, she directly held 16,225 shares of common stock. The sale was executed by a broker under a pre-arranged Rule 10b5-1 trading plan adopted on February 27, 2026, which company policy does not allow her to amend or modify after adoption.

Insider Trade Summary 10b5-1

Exercise and Sale: 2,261 shares ($176K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Delaet Ingrid

Role Chief Regulatory Officer

Sold 2,261 shs ($354K)

Approx. gross sale proceeds $354K

Approx. exercise cost $179K

Approx. pre-tax spread $176K

Type	Security	Shares	Price	Value
Exercise	Non-Qualified Stock Option	2,261	$0.00	$0.00
Exercise	Common Stock	2,261	$79.02	$179K
Sale	Common Stock	2,261	$156.71	$354K

Holdings After Transaction: Non-Qualified Stock Option — 0 contracts (Direct); Common Stock — 16,225 shares (Direct)

Footnotes (2)

1. F1. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
2. F2. The option was granted January 31, 2022 and vested in 48 equal monthly installments beginning February 28, 2022.

Key Figures

Shares sold: 2,261 shares Sale price: $156.71 per share Option exercise price: $79.02 per share +5 more

8 metrics

Shares sold 2,261 shares Open-market sale of common stock on May 29, 2026

Sale price $156.71 per share Average price for 2,261 NBIX shares sold May 29, 2026

Option exercise price $79.02 per share Exercise price for 2,261 non-qualified stock option shares

Shares held after 16,225 shares Direct NBIX common stock holdings after transactions

Option grant date January 31, 2022 Grant date of the non-qualified stock option exercised

Option expiration January 31, 2032 Expiration date of the exercised non-qualified stock option

10b5-1 plan adoption February 27, 2026 Adoption date of the Rule 10b5-1 trading plan

Options exercised 2,261 options Non-qualified stock options converted into common shares

Key Terms

Rule 10b5-1 trading plan, Non-Qualified Stock Option, open-market sale, Exercise or conversion of derivative security, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"The disposition was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted..."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Non-Qualified Stock Option financial

"security_title: "Non-Qualified Stock Option" with 2,261 underlying common shares..."

A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.

open-market sale financial

"transaction_action: "open-market sale" for 2,261 shares of common stock..."

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Exercise or conversion of derivative security financial

"transaction_code_description: "Exercise or conversion of derivative security" for the option exercise..."

vesting in 48 equal monthly installments financial

"The option was granted January 31, 2022 and vested in 48 equal monthly installments beginning February 28, 2022..."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did NBIX Chief Regulatory Officer Ingrid Delaet report?

Ingrid Delaet reported exercising options for 2,261 NBIX shares at $79.02 and selling 2,261 shares at $156.71. These same-day transactions reflect an exercise-and-sell pattern, converting an option position into cash while maintaining a remaining direct shareholding.

How many NEUROCRINE BIOSCIENCES (NBIX) shares does Ingrid Delaet hold after this Form 4?

Following the reported transactions, Ingrid Delaet directly holds 16,225 NBIX common shares. This figure reflects her position after exercising non-qualified stock options for 2,261 shares and selling 2,261 shares in an open-market transaction on May 29, 2026.

At what prices did Ingrid Delaet exercise and sell NBIX shares on May 29, 2026?

She exercised non-qualified stock options at an exercise price of $79.02 per share and sold 2,261 NBIX common shares at an average price of $156.71 per share. This captures the spread between her option strike price and the sale price that day.

Was Ingrid Delaet’s NBIX share sale made under a Rule 10b5-1 trading plan?

Yes. The sale was executed by a broker following instructions in a Rule 10b5-1 trading plan adopted on February 27, 2026. Company policy restricts her from amending or modifying this plan after adoption, indicating the trades were pre-scheduled rather than opportunistic.

What NBIX stock options did Ingrid Delaet exercise according to this Form 4?

She exercised a non-qualified stock option for 2,261 underlying NBIX shares with a $79.02 exercise price. The option was granted on January 31, 2022 and vested in 48 equal monthly installments beginning February 28, 2022, with expiration on January 31, 2032.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/02/2026 - 06:03 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Delaet Ingrid

(Last) (First) (Middle)

6027 EDGEWOOD BEND CT.

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NEUROCRINE BIOSCIENCES INC [ NBIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Regulatory Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/29/2026		M		2,261	A	$79.02	18,486	D
Common Stock	05/29/2026		S(1)		2,261	D	$156.71	16,225	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option	$79.02	05/29/2026		M			2,261	(2)	01/31/2032	Common Stock	2,261	$0	0	D

Explanation of Responses:

1. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

2. The option was granted January 31, 2022 and vested in 48 equal monthly installments beginning February 28, 2022.

Remarks:

	/s/ Darin Lippoldt, Attorney-in-Fact	06/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)